Olmesartan medoxomil for the treatment of hypertension in children and adolescents

References

• ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• WilliamsBPoulterNRBrownMJGuidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IVJ Hum Hypertens200418313918514973512
   PubMed Web of Science ®Google Scholar
• NealBMacMahonSChapmanNEffects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ CollaborationLancet200035692461955196411130523
   PubMed Web of Science ®Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• TurnbullFNealBAlgertCEffects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trialsArch Intern Med2005165121410141915983291
   PubMedGoogle Scholar
• TurnbullFNealBNinomiyaTEffects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trialsBMJ200833676531121112318480116
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA2003289182363236912746359
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension2004431101714638619
   PubMed Web of Science ®Google Scholar
• NakamuraKBarziFLamTHCigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific regionStroke20083961694170218323508
   PubMed Web of Science ®Google Scholar
• MartiniukALLeeCMLawesCMHypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific regionJ Hypertens2007251737917143176
   PubMed Web of Science ®Google Scholar
• BarziFPatelAWoodwardMA comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific regionAnn Epidemiol200515540541315840555
   PubMed Web of Science ®Google Scholar
• KelishadiRArdalanGGheiratmandRBlood pressure and its influencing factors in a national representative sample of Iranian children and adolescents: the CASPIAN StudyEur J Cardiovasc Prev Rehabil12200613695696317143128
   PubMedGoogle Scholar
• GenovesiSAntoliniLGallieniMHigh prevalence of hypertension in normal and underweight Indian childrenJ Hypertens201129221722121045730
   PubMed Web of Science ®Google Scholar
• RumboldtMPavlicevicIKuzmanicMRumboldtZPrevalence of hypertension in school childrenJ Hypertens2008263610611 author reply61161218300878
   PubMed Web of Science ®Google Scholar
• SorofJMLaiDTurnerJPoffenbargerTPortmanRJOverweight, ethnicity, and the prevalence of hypertension in school-aged childrenPediatrics20041133 Pt 147548214993537
   PubMed Web of Science ®Google Scholar
• SorofJMPrevalence and consequence of systolic hypertension in childrenAm J Hypertens2002152 Pt 257S60S11866232
   PubMed Web of Science ®Google Scholar
• KelishadiRChildhood overweight, obesity, and the metabolic syndrome in developing countriesEpidemiol Rev200729627617478440
   PubMed Web of Science ®Google Scholar
• McQueenMJHawkenSWangXLipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control studyLancet2008372963422423318640459
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• BaoWThreefootSASrinivasanSRBerensonGSEssential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart StudyAm J Hypertens1995876576657546488
   PubMed Web of Science ®Google Scholar
• ChenWSrinivasanSRRuanLMeiHBerensonGSAdult hypertension is associated with blood pressure variability in childhood in blacks and whites: the bogalusa heart studyAm J Hypertens2011241778220725054
   PubMed Web of Science ®Google Scholar
• BerensonGSWattigneyWABaoWNicklasTAJiangXRushJAEpidemiology of early primary hypertension and implications for prevention: the Bogalusa Heart StudyJ Hum Hypertens1994853033118064774
   PubMed Web of Science ®Google Scholar
• VolpeMErhardtLRWilliamsBManaging cardiovascular risk: the need for changeJ Hum Hypertens200822215415717855801
   PubMed Web of Science ®Google Scholar
• WilliamsBRecent hypertension trials: implications and controversiesJ Am Coll Cardiol200545681382715766813
   PubMed Web of Science ®Google Scholar
• LurbeECifkovaRCruickshankJKManagement of high blood pressure in children and adolescents: recommendations of the European Society of HypertensionJ Hypertens20092791719174219625970
   PubMed Web of Science ®Google Scholar
• The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescentsPediatrics20041142 Suppl 4th Report55557615286277
   PubMed Web of Science ®Google Scholar
• Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education ProgramNational High Blood Pressure Education Program Working Group on Hypertension Control in Children and AdolescentsPediatrics1996984 Pt 16496588885941
   PubMed Web of Science ®Google Scholar
• YamadaSPleiotropic effects of ARB in metabolic syndromeCurr Vasc Pharmacol20119215816121143168
   PubMed Web of Science ®Google Scholar
• SaitohSTakeishiYPleiotropic effects of ARB in diabetes mellitusCurr Vasc Pharmacol20119213614421143171
   PubMed Web of Science ®Google Scholar
• PapadopoulosDPPapademetriouVMakrisTKOn target to dual block RAS?Angiology200960673974919144653
   PubMed Web of Science ®Google Scholar
• SimonettiGDRizziMDonadiniRBianchettiMGEffects of anti-hypertensive drugs on blood pressure and proteinuria in childhoodJ Hypertens200725122370237617984655
   PubMed Web of Science ®Google Scholar
• HazanLHernandez RodriguezOABhoratAEMiyazakiKTaoBHeyrmanRA double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertensionHypertension20105561323133020385971
   PubMed Web of Science ®Google Scholar
• WarnerGTJarvisBOlmesartan medoxomilDrugs200262913451353 discussion1354134612076183
   PubMed Web of Science ®Google Scholar
• VolpeMMusumeciBDe PaolisPSavoiaCMorgantiAAngiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?J Hypertens20032181429144312872031
   PubMed Web of Science ®Google Scholar
• BrunnerHROlmesartan medoxomil: current status of its use in monotherapyVasc Health Risk Manag20062432734017323586
   PubMedGoogle Scholar
• PuchlerKLaeisPStumpeKOBlood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonistJ Hypertens Suppl2001191S41S4811451214
   PubMedGoogle Scholar
• UsuiMEgashiraKTomitaHImportant role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in ratsCirculation2000101330531010645927
   PubMed Web of Science ®Google Scholar
• TakemotoMEgashiraKTomitaHChronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesisHypertension1997306162116279403592
   PubMed Web of Science ®Google Scholar
• TomitaHEgashiraKOharaYEarly induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in ratsHypertension19983222732799719054
   PubMed Web of Science ®Google Scholar
• KoikeHSadaTMizunoMIn vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonistJ Hypertens Suppl2001191S3S1411451212
   PubMedGoogle Scholar
• ScottLJMcCormackPLOlmesartan medoxomil: a review of its use in the management of hypertensionDrugs20086891239127218547134
   PubMed Web of Science ®Google Scholar
• UngerTMcInnesGTNeutelJMBohmMThe role of olmesartan medoxomil in the management of hypertensionDrugs200464242731273915563246
   PubMed Web of Science ®Google Scholar
• BrousilJABurkeJMOlmesartan medoxomil: an angiotensin II-receptor blockerClin Ther20032541041105512809956
   PubMed Web of Science ®Google Scholar
• SchwochoLRMasonsonHNPharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjectsJ Clin Pharmacol200141551552711361048
   PubMed Web of Science ®Google Scholar
• Von BergmannKLaeisPPuchlerKSudhopTSchwochoLRGonzalezLOlmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomilJ Hypertens Suppl2001191S33S4011451213
   PubMedGoogle Scholar
• StumpeKOOlmesartan compared with other angiotensin II receptor antagonists: head-to-head trialsClin Ther200426Suppl AA33A3715291378
   PubMedGoogle Scholar
• WehlingMCan the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?Clin Ther200426Suppl AA21A2715291376
   PubMedGoogle Scholar
• LaeisPPuchlerKKirchWThe pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interactionJ Hypertens Suppl2001191S21S3211451211
   PubMedGoogle Scholar
• MuirVJKeatingGMOlmesartan medoxomil: in children and adolescents with hypertensionDrugs201070182439244721142262
   PubMed Web of Science ®Google Scholar